Lidocaine Hydrochloride Topical Solution Recalled for Manufacturing Quality Deviations
McKesson Corporation is recalling Lidocaine Hydrochloride Topical Solution due to manufacturing deviations related to discontinuation of the stability study program. Approximately 81,757 bottles distributed nationwide are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall due to CGMP deviations related to discontinued stability studies, representing a risk-of-harm situation where the product's long-term safety and efficacy cannot be assured. No illnesses or injuries have been reported.
Plain-English summary
McKesson Corporation is recalling Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL bottles (Rx only), manufactured by Teligent Pharma, Inc., Buena, New Jersey.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The manufacturing firm discontinued its stability study program. Stability studies are used to demonstrate that products maintain their labeled potency and quality throughout their shelf life.
Approximately 81,757 bottles have been distributed nationwide in the United States, Guam, and the Northern Mariana Islands. The affected lot numbers and expiration dates are: Lot 15597 (Exp. 05/31/2023), Lot 16305 (Exp. 12/23/2023), Lot 16334 (Exp. 01/31/2024), Lot 16340 (Exp. 01/31/2024), Lot 16346 (Exp. 01/31/2024), Lot 16356 (Exp. 01/31/2024), and Lot 16357 (Exp. 01/31/2024).
Patients who have received this product should contact their healthcare provider for guidance on alternative treatments. Unused product should be returned to the dispensing pharmacy.
The recalled product
- Product
- Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL bottle, Rx only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Distributed by: McKesson Corporation dba Sky Packaging 4071 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-977-64
- Manufacturer
- McKesson Corporation dba McKesson Drug Company
- Category
- Drug — Topical Anesthetic
- Affected units
- 81,757
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lots: 15597
- Exp.: 05/31/2023
- 16305
- Exp.: 12/23/2023
- 16334
- Exp.: 01/31/2024
- 16340
- 16346 Exp.: 01/31/2024
- 16356
- 16357
Distribution
Part of a larger recall action
This product is one of 5 recalled by McKesson Corporation dba McKesson Drug Company under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · McKesson Corporation dba McKesson Drug Company
See all →- ModerateErythromycin Topical Gel Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2022-05-11
- HighBetamethasone Dipropionate Ointment 0.05% recalled for manufacturing compliance failures
FDA (Drugs) · 2022-05-11
- HighHalobetasol Propionate Ointment 0.05% Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2022-05-11
- HighFDA Recalls Lidocaine Prilocaine Cream Due to Manufacturing Compliance Issue
FDA (Drugs) · 2022-05-11
- ModerateLevetiracetam Tablets 250 mg Recalled for Incorrect Barcode
FDA (Drugs) · 2021-06-16
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19